Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAGE A10 CAR-T in advanced NSCLC
NCT02592577Phase 1Completed
- Sponsor
- Adaptimmune Therapeutics
- Start
- Nov 2015
- Primary completion
- Mar 2020
- Modality
- Prophylactic Vaccines, Gene Editing, Gene Silencing
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of MAGE-A10c796T in non-small cell lung cancer (NSCLC), sponsored by Adaptimmune Therapeutics. Primary endpoints: Dose-Limiting Toxicity at 24 months and Adverse Events at 24 months. Started Nov 2015; status: completed.
02
Drugs
MAGE-A10c796T
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02592577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02592577.